A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bleomycin; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Prednisolone; Vincristine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 09 Aug 2019 Status changed from suspended to active, no longer recruiting.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 03 May 2019 Status changed from recruiting to suspended.